Our Biosensor Platform composed of a biomolecular analyzer, SENEDIA, and semiconductor-based biosensors is developed on SiNW-FET core technology. Results come out real-time upon changes in electrical signals caused by the interaction between bio-probes modified on biosensors and targets in samples.
Our detection limit is 10-15M that’s a lot more sensitive than Q-PCR’s 10-5 M, thus breaking the limit of this technology commonly used to detect residual pathogens for Acute Myeloid Leukemia.
Besides disease detection, our ultrahigh sensitive, high accuracy, fast, and easy-to-use biosensor platform is expandable to food safety, environmental monitoring, animal tests, and etc. We received an EUA for COVID-19 RNA rapid testing and are leveraging our establishment for the evaluation of treatment on AML.
Our platform is built on Taiwan’s semiconductor infrastructure to facilitate a local medical device manufacturing chain, leading Taiwan to be the medical detection hub of next generation.